Friday, Jul 10, 2020 | Last Update : 12:08 AM IST

107th Day Of Lockdown

Maharashtra2305991272599667 Tamil Nadu122350741671700 Delhi104864781993213 Gujarat38419273131994 Uttar Pradesh3115620331845 Telangana2953617279324 Karnataka2887711878471 West Bengal2482316291827 Andhra Pradesh2381412154277 Rajasthan2221216877489 Haryana1936414505287 Madhya Pradesh1634112232634 Assam14033872724 Bihar139789792109 Odisha11201740767 Jammu and Kashmir92615567149 Punjab71404945183 Kerala6535370828 Chhatisgarh3526283514 Uttarakhand3305267246 Jharkhand3192217022 Goa203912078 Tripura177313241 Manipur14357930 Puducherry120061916 Himachal Pradesh110182510 Nagaland6733030 Chandigarh5234037 Arunachal Pradesh2871092 Mizoram2031430 Sikkim134710 Meghalaya113451
  World   Europe  06 Jun 2020  British scientists halt hydroxychloroquine trial, call it 'useless'

British scientists halt hydroxychloroquine trial, call it 'useless'

REUTERS
Published : Jun 6, 2020, 3:42 pm IST
Updated : Jun 6, 2020, 5:40 pm IST

The malaria drug was touted by U.S. President Donald Trump as a potential “game changer” in the pandemic

 A bottle and pills of Hydroxychloroquine. (AFP)
  A bottle and pills of Hydroxychloroquine. (AFP)

London: British scientists halted a major drug trial on Friday after it found that the anti-malarial hydroxychloroquine, touted by U.S. President Donald Trump as a potential “game changer” in the pandemic, was “useless” at treating COVID-19 patients.

“This is not a treatment for COVID-19. It doesn’t work,” Martin Landray, an Oxford University professor who is co-leading the RECOVERY trial, told reporters.

“This result should change medical practice worldwide. We can now stop using a drug that is useless.”

Vocal support from Trump raised expectations for the decades-old drug that experts said could have been a cheap and widely available tool, if proven to work, in fighting the pandemic, which has infected more than 6.4 million people and killed nearly 400,000 worldwide

Controversy surrounding the drug grew after a study published in medical journal The Lancet last month raised safety concerns and led several COVID-19 studies of it to be halted. The Lancet study was then retracted on Thursday after its authors said they were unsure about its data.

Landray, a professor of medicine and epidemiology at Oxford University, noted the “huge speculation” about the drug as a treatment for COVID-19 but said there had been until now “an absence of reliable information from large randomised trials”.

He said the preliminary results from RECOVERY, which was a randomised trial, were now quite clear: hydroxychloroquine does not reduce the risk of death among hospitalised patients with COVID-19.

“If you’re admitted to hospital, don’t take hydroxychloroquine,” he said.

The RECOVERY trial of hydroxychloroquine had randomly assigned 1,542 COVID-19 patients to hydroxychloroquine and compared them with 3,132 COVID-19 patients randomly assigned to standard care without the drug.

Results showed no significant difference in death rates after 28 days, in length of stay in hospital or in other outcomes, the researchers said.

The World Health Organization (WHO) said on Wednesday it would resume tests of hydroxychloroquine as part of its ‘Solidarity’ trials, after those running the study briefly stopped giving it to new patients in light of the Lancet paper.

Peter Horby, an Oxford University professor who is co-leading the RECOVERY trial with Landray, said his team had informed the WHO of their decision to halt the UK study.

“There was a call this morning with the WHO to give them a heads-up on the results... They... said they would be convening their committee to look again at their decision regarding the Solidarity trial.”

Tags: hydroxychloroquine, donald trump, anti-malaria drug